Ascendis Pharma A/S To Present At ENDO 2015

COPENHAGEN, Denmark, March 5, 2015 /PRNewswire/ -- Ascendis Pharma A/S, a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced that it will present two posters at the ENDO 2015 conference being held at the San Diego Convention Center.  The posters will be presented on Thursday, March 5, 2015 during the Pediatric EndocrinologyClinical/Translational Session that is being held from 1:00pm-3:00pm PST, and are titled:

TransCon Human Growth Hormone a Once-Weekly Prodrug of Recombinant Human Growth Hormone: Design, Characterization and PK/PD in Growth Hormone Deficient (GHD) Adults

Six-Month Interim Safety and Efficacy of Different Dose Levels of TransCon hGH Administered Once-Weekly Versus Standard Daily Human Growth Hormone Replacement Therapy in Pre-Pubertal Children with Growth Hormone Deficiency (GHD)


Ascendis Pharma logo

About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained release technologies, to develop a pipeline of best-in-class therapeutics that address significant unmet medical needs.  The TransCon technology can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug.   

The Ascendis Pharma pipeline includes TransCon Growth Hormone, a proprietary program that has completed a Phase 2 study in adults with growth hormone deficiency, or GHD.  Ascendis Pharma is currently conducting a Phase 2 study of TransCon Growth Hormone in children with GHD.  Ascendis Pharma is also developing its wholly-owned TransCon Treprostinil for the treatment of pulmonary arterial hypertension, or PAH.  TransCon Treprostinil is currently in a Phase 1 single ascending dose study in healthy volunteers.  In addition to its proprietary programs, Ascendis Pharma has formed collaborations focused on leading products in large markets that are of strategic importance to its collaboration partners.  These collaborations are with Sanofi in diabetes and Genentech in the field of ophthalmology.


Investor Relations:
Martin Auster, M.D.
Chief Business Officer
(650) 617-3403

Media Relations:
Marion Janic
Rooney & Associates 
(212) 223-4017

Logo -


To view the original version on PR Newswire, visit:

SOURCE Ascendis Pharma A/S

Help employers find you! Check out all the jobs and post your resume.

Back to news